Note 1 - Formation and Business of the Company (Details Textual) - USD ($)				1 Months Ended	3 Months Ended			9 Months Ended		23 Months Ended	41 Months Ended	42 Months Ended
	Oct. 06, 2022	Nov. 06, 2020	Jun. 01, 2016	Oct. 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Nov. 30, 2019	Nov. 30, 2019	Aug. 31, 2021
Revenue from Contract with Customer, Excluding Assessed Tax, Total					$ 4,956,000	$ 2,412,000		$ 7,663,000	$ 6,457,000
Cancer Prevention and Research Institute of Texas [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total											$ 20,000,000.0
Percentage of Cash Required to Raise in Matching Funds			50.00%
Cash Required to Raise in Matching Funds			$ 10,000,000.0
Matching Funds Required to Raise, Project Term (Year)			3 years
Cash Required in Matching Funds, Amount Raised												$ 10,000,000.0
Percentage of Grant Award Proceeds Required to Pay			400.00%
3D Medicines, Inc [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total								3,100,000
Proceeds from Collaborators								15,000,000		$ 27,000,000
Proceeds from Milestone Achievement							$ 6,000,000
Collaborative Agreement, Expected Milestone Payments to be Received													$ 3,000,000
3D Medicines, Inc [Member] | Subsequent Event [Member]
Proceeds from Collaborators				$ 6,000,000
Proceeds from Milestone Achievement	$ 6,000,000			$ 6,000,000
3D Medicines, Inc [Member] | Mainland China,Taiwan, Hong Kong and Macau [Member]
Proceeds from Collaborators		$ 12,000,000
Leland Stanford Junior University [Member]
Maximum Milestone Payments Upon Achievement of Clinical and Regulatory Milestones					$ 1,000,000			$ 1,000,000		$ 1,000,000